|Bid||0.9972 x N/A|
|Ask||1.0300 x N/A|
|Day's Range||0.9901 - 0.9901|
|52 Week Range||0.5200 - 1.2800|
|Beta (3Y Monthly)||0.85|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.01 (0.93%)|
|1y Target Est||N/A|
May 9 (Reuters) - Sino Biopharmaceutical Ltd: * 'AMBRISENTAN TABLET' DEVELOPED BY UNIT GETS APPROVAL FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC Source text for Eikon: Further ...
Nov 29 (Reuters) - Sino Biopharmaceutical Ltd: * SINO BIOPHARMACEUTICAL SAYS PARECOXIB SODIUM FOR INJECTION DEVELOPED BY UNIT GETS APPROVAL FOR DRUG REGISTRATION BY NMPA Source text for Eikon: Further ...
Sino Biopharmaceutical Limited, researches, develops, manufactures, and sells Chinese medicines and chemical medicines in Hong Kong, Mainland China, and internationally. Sino Biopharmaceutical’s insiders have invested more than 7 million sharesRead More...
In March 2018, Sino Biopharmaceutical Limited (HKG:1177) announced its earnings update. Overall, the consensus outlook from analysts appear fairly confident, as a 36.25% increase in profits is expected in theRead More...
Bank of East Asia Ltd. slumped the most since July 2015 following news it will be cut from Hong Kong’s Hang Seng Index along with China Merchants Port Holdings Co., which also tumbled. BEA closed down 5.8 percent Monday, making it the worst performer on the Hong Kong benchmark, even after paring some earlier losses. China Merchants Port was the third-worst, dropping the most since February.